Topic Listing for NOVO NORDISK A S

Accounting Non-monetary Transactions Accounting Policies
Accounting Policies Non-financial Data Achieved Goal Americans Diabetes Good Control Martin Soeters
Activelle Low Dose Additional Required Information
Addressing Dilemmas Adrs
Allowances Doubtful Trade Receivables Analyst Coverage
Animal Data Animals
Anne Marie Kverneland Annual Financial Report 2003
Annual Report Annual Report 2004
Annual Report 2006 Annual Report 2008
Appendix Accounting Policies Appendix Assumptions Key Currencies
Appendix Assumptions Key Currencies Operating Profit Sensitivity 2008 Appendix Balance Sheet
Appendix Cash Flow Statement Appendix Condensed Cash Flow Statement
Appendix Exchange Rates Key Currencies Appendix Income Statement
Appendix Statement Cash Flows Appendix Statement Financial Position
Approach Tailored Individual Assumptions
Assurance Report Non-financial Reporting 2004 Audit Committee
Audit Fees Audit Whistleblower
Audit-related Fees Auditors Report Annual 2004
Auditors Reports Auditors Responsibility
Available-for-sale Financial Assets Back Contents
Basic Employee Statistics Basis Conclusion
Biopharmaceuticals Biopharmaceuticals Other Main Business Area Accounts Overall Sales
Board Directors Board Members
Board Members Executives Associated Persons Board Practices
Board Practises Bullet-proof Vest Epidemic Chronic Disease Prevention Stig Pramming
Business Environment Values Action Business Ethics Training Deals Dilemmas
Business Overview Business Performance
Business Results Diabetes Care Biopharmaceuticals Challenging Workplace Values Business Results Financial Non-financial Performance
Call Action Initiative Improve Conditions Women Diabetes Capacity-building
Capital Expenditure Capital Expenditure 2004 2003 2002
Capital Expenditure Free Cash Flow Capital Markets
Capital Structure Carbon Future
Cash Earnings Cash Flow
Cash Value Distribution 2006 Catalyst Change
Certification Effectiveness Disclosure Controls Procedures Form 20-f 2005 Certification Effectiveness Disclosure Controls Procedures Form 20-f 2006
Certification Effectiveness Disclosure Controls Procedures Form 20-f 2007 Certification Effectiveness Disclosure Controls Procedures Form 20-f 2008
Certification Lars Rebien SØrensen Chief Executive Officer Novo Chairmanship
Challenges Ahead Challenging Workplace Innovation Performance Quality Mindset Sets Standard
Changes Internal Controls Over Financial Reporting Changes Scope Consolidation
Changing Diabetes Campaign Changing Diabetes Demands New Approaches
Clinical Trials Therapy Area 2006 Highlights Column
Commentary Commitments Capital Expenditure Etc
Commitments Contingencies Commitments Triple Bottom Line
Compared 2002 Compared 2003
Compensation Completeness
Compliance Compliance Data
Compliance Sarbanes-oxley Requirements Conclusion
Conference Call Details Consolidated Financial Non-financial Statements 2007
Consolidated Financial Statements Definitions Consolidated Financial Statements Income Statement
Consolidated Financial Statements Management Statement Consolidated Financial Statements Notes Accounting Policies
Consolidated Financial Statements Notes Additional Information Consolidated Financial Statements Statement Schedules
Consolidated Non-financial Statements Consolidated Non-financial Statements Notes Accounting Policies Data
Consolidated Non-financial Statements Notes Performance Indicators Consolidated Non-financial Statements Overview Reporting
Consolidated Statement Cash Flows Financial Resources Consolidated Statements Other Financial Information
Contact Contacts
Contacts Further Information Contents
Control Matters Convenient Insulin Delivery
Corporate Governance Corporate Governance Benchmark 2007
Corporate Governance Codes Practices Corporate Governance Refers Way Managed Major Principles Frameworks
Costs Licence Fees Other Operating Income Counterparty Risk
Critical Accounting Estimates Critical Accounting Policies
Data Debt Financing
Definitions Background Information Depreciations Amortisation Impairment Losses
Derivative Financial Instruments Development Gross Margin Costs
Diabetes Care Diabetes Care Changing
Diabetes Care Sustaining Leadership Diabetes Care Worlds Leading
Diabetes Prevention Diabetes Treatment
Diabetes Youth Charter Addresses Burden Juvenile Diabetologia
Directors Executive Management Directors Senior Management
Disclosure Regarding Change Control Diversity Supports Global Growth
Dividend Payment Dividend Policy
Dividends Documents Display
Doing Business Novo Nordisk Way Eco-productivity Indices Epi
Economics Effects New Accounting Pronouncements
Eitf Issue 03-1 Emerging Markets Move
Emissions Air Emissions Below 2004 Baseline
Employee Benefits Employee Share Programme
Employee Shares Employees
Employees Takeaction Enforceability Civil Liabilities
Ensuring Access Care Environmental Impact Potentials
Environmental Impacts Environmental Strategy Builds Business Case
Epi Water Energy Equity
Equity Liabilities Ethical Practices Guide Medical Research
Europe Europe Modern Insulin Growth
Evaluation Disclosure Controls Procedures Evaluation Performance
Exchange Controls Exchange Rates
Exchanges Non-monetary Assets Executive Management
Executives Exhibits
Expanded Haemophilia Pipeline Expanding Access Treatment
Expanding Range Biopharmaceuticals Expanding Scope Biopharmaceuticals
Expectation Operating Profit Growth 2005 Increased 12-15 Facing Leadership Challenge
Financial Assets Financial Assets Fair Value Through Profit Loss
Financial Calendar Financial Calendar 2007
Financial Calendar 2008 Financial Calendar 2009
Financial Calendar 2010 Financial Definitions
Financial Exposure Risk Management Financial Instruments
Financial Non-financial Statements 2005 Financial Outlook
Financial Resources Focus Opportunities Bric Countries
Focus Strength Focused Strategy Targets Diabetes Crisis
Focusing Strengths Biopharmaceuticals Foreign Currencies
Foreign Exchange Risk Foreign Exchange Sensitivity Analysis
Form 20-f Forward-looking Statement
Forward-looking Statements Free Cash Flow
Fsp 106-2 Fulfilment Action Points
Functional Presentation Currency Future Builds Core Competences
Get Touch Goodwill
Governance Structure Governmental Policies Please Refer Pages 20-25 Business Strategy
Green Electricity Novo Nordisk Denmark Growth Every Level
Growth Hormone Therapy Norditropin Growth Hormone Therapy Norditropin Simplexx
Guardian Haemophilia Foundation Project Launched
Health Safety Health-economic Studies Aid Decision-making
Hedging Net Investments Foreign Subsidiaries Hilda Thanks Making Real Difference
History Development Holding Treasury Shares Share Repurchase Programme
Hormone Therapy Litigation Impact Regulations
Impairment Assets Important Events 2004
Improved Prevention Detection Treatmen Income Taxes
Indirect Production Costs Ipcs Industry News
Inflation Insulin Analogues Human Insulin-related Products
Intangible Assets Interest Rate Risk
Interest Rate Sensitivity Analysis Internal Control Over Financial Reporting
International Financial Reporting Standards International Operations
Internet Inventories
Inventory Costs Amendment Arb No43 Chapter Pricing Inventory Pricing
Investigation Related United Nations Oil-for-food Programme Investments Associated Companies
Invoicing Currency Italian Insulin Litigation
Japan Oceania Japan Oceania Leading Market
Jesper Brandgaard Jesper Brandgaard Executive Vice President Chief Financial Officer
Johnny Henriksen Jørgen Wedel
Kurt Anker Nielsen Kurt Briner
Kåre Schultz Kåre Schultz Chief Operating Officer Novo Nordisk
Kåre Schultz Executive Vice President Chief Operating Officer Lancet
Lars Almblom Jørgensen Lars Rebien Sørensen
Lars Rebien Sørensen President Ceo Novo Nordisk Launch-share Option Plan
Leading Passion Leases
Legal Issues Novo Nordisk Party Number Cases See Legal Issues Update
Legal Proceedings Leveraging Protein Strengths Fight Inflammation
Liabilities Liability Debts Obligations Novozymes Following Demerger 2000
Licence Fees Other Operating Income Net Liquidity Capital Resources
Liquidity Risk Liraglutide Key Future Growth
Liraglutide Phase Programme Liraglutide Shows Solid Potential
Lise Kingo Litigation
Living Haemophilia Living Values
Loans Receivables Long-term Incentive Programmes
Long-term Presence Emerging Markets Pays Off Long-term Share-based Incentive Programme
Looking Cost Diabetes Mads Krogsgaard Thomsen
Mads Øvlisen Chairman Maintaining Edge
Major Shareholders Management Report
Management Report Discussion Management Statement
Managements Remuneration Share Options Shareholdings Managements Responsibility
Managements Responsibility Annual Report Managing Global Supply Chain
Managing Responsibly Managing Risks
Marketing Competition Markets
Material Contracts Materiality
Measuring Progress Media Debate Novoseven Combat Zones
Memorandum Articles Association Modern Insulin Portfolio
Modern Insulins Available People Modern Insulins Human Insulin Insulin-related Products
Modern Insulins Human Insulin-related Products Modern Insulins Human Protein-related Products
Net Financial Expense Net Financial Income
Net Financials Net Financials Tax
New Accounting Pronouncements New England Journal Medicine
News Pipeline Niels Jacobsen
Non-recurring Costs Related Discontinuation Pulmonary Diabetes Projects Norditropin
North America Notes Accounting Policies
Notes Columns Novo Allé Dk-2880 Bagsværd Denmark Address Principal Executive
Novo Nordisk Novo Nordisk 2006 Sales Grew Driven Modern Insulins
Novo Nordisk Achieves High Score Dow Jones Sustainability Novo Nordisk Aims Communicating Openly Stakeholders Financial Business
Novo Nordisk Annual Report 2008 Novo Nordisk Annual Report 2008 107
Novo Nordisk Annual Report 2008 113 Novo Nordisk Changing Diabetes
Novo Nordisk Continues Make Progress Towards Label Expansion Novo Nordisk Expects Slightly Growth Sales Measured Local
Novo Nordisk Focused Healthcare Headquartered Denmark World Leader Novo Nordisk Increased Half-year Sales Local Currencies Improved
Novo Nordisk Increased Operating Profit Novo Nordisk Increased Operating Profit 2007 Based Sales
Novo Nordisk Increased Operating Profit 2008 Expectations Growth Novo Nordisk Increased Operating Profit 2009
Novo Nordisk Increased Operating Profit 2009 Raises Outlook Novo Nordisk Increased Sales 2006
Novo Nordisk Increased Sales Operating Profit 2006 Novo Nordisk Investor Relations
Novo Nordisk Key Products Novo Nordisk Ranks Access Medicine Index
Novo Nordisk Rated Healthcare Leader Dow Jones Sustainability Novo Nordisk Way
Novo Nordisk Way Management Novo Nordisk Way Management Forms Values-based Governance Framework
Novo Nordisks Economic Stakeholder Model Novo Nordisks Remuneration Policy Board Directors Executive Management
Novo Nordisks Vision Novoseven
Off-balance Sheet Arrangements Offer Listing Details
Online Report Available Novonordiskcom Annual-report Opening Statement Review
Operating Performance Operating Profit
Operating Results Opinion
Oral Antidiabetic Products Oral Antidiabetic Products Novonorm Prandin
Ordinary Share Option Plans Organizational Structure
Other Accounting Policies Other Fees
Other Financial Data Other Intangible Assets
Other Litigation Proceedings Other Members Senior Management Board
Other Products Other Reserves
Outlook Outlook 2006
Outlook 2007 Outlook 2008
Outlook 2009 Part
Passing Ethical Test Patent Families
Patent Infringement Litigation Patents
Payment Dividends Pending Claims Against Novo Nordisk Investigations Involving
Pending Litigation Against Novo Nordisk Pensions
People Strategy Framework Continue Inspire Engage Develop Employees People Values Make Difference
Performance Performance 2007
Performance Highlights Pioneering Efforts
Pipeline Overview Pipeline Progress
Potential Treatment Dialysis Patients Pre-approval Policies
Preparing Low President Chief Executive Officer Ceo
Prevention Chronic Diseases Hope Future Price Development Monthly Turnover Novo Nordisks Shares Omx
Principles Consolidation Property Plant Equipment
Property Plants Equipment Proposed Dividend Payment 2007
Proposed Dividend Payment 2008 Proposed Dividend Reduction Share Capital
Provisions Provisions Contingencies
Public Affairs Roadmap Changing Diabetes Public Takeover Offers Respect Shares Such Occurred 2005
Public Takeover Offers Respect Shares Such Occurred 2006 Public Takeover Offers Respect Shares Such Occurred 2007
Publication Pursuing Options Treatment Administration
Pursuing Promising Leads Haemophilia Raw Materials
Readers Guide Reasons Offer Proceeds
Recognition Measurement Reduction Share Capital
References Related Party Transactions
Report Foreign Issuer Pursuant Rule 13a-16 15d-16 Securities Report Foreign Private Issuer Pursuant Rule 13a-16 15d-16
Report Independent Registered Public Accounting Firm Reporting Against Global Standards
Research Development Research Development Facilitator
Research Development Patents Licenses Etc Research Development Progress
Research Development Update Research Development Update Diabetes Care
Resolution Diabetes Resources
Responsible Sourcing Revisiting Strategy Responsiveness
Results Right Care
Risk Factors Risk Management
Sales Sales Adrs Shares
Sales Development Regions Sales Development Segments
Sales Growth Sales Rebate Accruals Provisions
Sales Revenue Recognition Scope
Seasonality Segment Information
Segment Reporting Selected Financial Data
Sensitivity Analysis Setting Agenda Change
Setting Long-term Targets Share Based Payment
Share Capital Ownership Share Highlights
Share Option Programme Share Options
Share Options Novozymes Share Ownership
Share Price Performance Share-based Compensation
Shareholder Information Shareholder Information Board Directors
Shareholder Information Corporate Governance Shareholder Information Shares
Shareholders Novo Nordisk Sharing Treatment Best Practices
Shortage Experts Statistics Sounding Alarm Diabetes Epidemic Still Signatures
Significant Accounting Estimates Significant Changes
Social Impacts Solostar Litigation
Spotlight Access Health Spotlight Business Ethics
Spotlight Globalisation Spotlight Innovation
Standards Early Adopted Group Standards Not Adopted Group
Statement Board Directors Executive Management Annual Report Statement Comprehensive Income
Statement Financial Accounting Standards 123 Sfas 123r Statement Financial Accounting Standards 151 Sfas
Statement Financial Accounting Standards 153 Sfas Statutory Audit
Sten Scheibye Vice Chairman Stig Strøbæk
Strategy Expand Leadership Subject Responsibilities Objective Scope Assurance Statement
Subpoena Related Sales Promotion Practices Subsidiary Information
Summary Significant Accounting Policies Super Sector Leader
Supporting Individualised Treatment Options Sustainability Issues Update
Tabular Disclosure Contractual Obligations Tailored Solutions
Tax Tax Fees
Tax Rate Taxation
Terje Kalland Head Novo Nordisk Biopharmaceuticals Research Unit Time Act
Total Hedging Activities Trading Novo Nordisk Shares Board Members Executives Associated
Training Costs Translation Foreign Currencies
Translation Group Companies Translation Transactions Balances
Treasury Shares Treasury Shares Share Repurchase Programme
Tremendous Responsibility Customers Every People Put Lives Hands Trend Information
Ulf Johansson United Change Diabetes
United Nations Oil-for-food Programme Universal Principles Guide Action
Unmet Medical Needs Haemophilia Vice-chairman Board Directors
Vision Washington 20549
Waste Waste Water
Welcome Novo Nordisk Glance Welcome Novo Nordisk Letter
What Date Place Transaction What Financial Instrument Code
What Trading Transaction What Volume Value Transaction
Whistleblower Programme World Diabetes Foundation
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki